IL2RA and COVID-19: Consequently, the administration of BDs of the mRNA COVID-19 vaccine was found to be safe, although transient alteration of systemic inflammation status is expected as a result of T cell priming (IL2-R, IL-6, TNF-α), followed by the deactivation (IL-10) of pro-inflammatory cytokine synthesis [29].